2 min read
Are you stepping into the world of pharmaceuticals in Brazil? Have you ever wondered how medicinal products or drugs are approved in the country? Understanding the drug approval process in Brazil is essential for companies planning to introduce medicines into this market.
In this blog, we unveil thirteen (13) must-know Frequently Asked Questions (FAQs) about ANVISA and drug registration in Brazil, designed to help you understand the fundamentals of pharmaceutical approval in a clear and practical way.
1. What is ANVISA?
The Agência Nacional de Vigilância Sanitária (ANVISA), or the National Health Surveillance Agency, is the Brazilian health regulatory authority responsible for evaluating whether medicines are safe, effective, and compliant with regulatory standards before they reach patients. In simple terms, ANVISA ensures that medicinal products marketed in Brazil meet quality and safety requirements.
2. Who is eligible to apply for new drug approval in Brazil?
- Pharmaceutical companies legally established in Brazil and authorized to operate before the Brazilian Health Regulatory Agency (ANVISA).
- Foreign pharmaceutical companies must submit applications through a Brazilian legal entity holding the appropriate regulatory authorization.
3. What kinds of drugs require approval in Brazil?
- All new drugs, including prescription and over-the-counter (OTC) medicines
- Biologics, such as vaccines and insulin
- Generic drugs
4. What are the main steps involved in the drug approval process?
- Pre-clinical studies to assess safety and efficacy
- Clinical trials conducted in defined phases
- Registration application submitted with a complete dossier to ANVISA
- Technical evaluation by ANVISA experts
- Approval or rejection based on regulatory review
- Pricing approval by the Drug Market Regulation Chamber (CMED), when applicable, prior to commercialization in the Brazilian market.
5. How can you be sure a drug is safe to be placed on the Brazilian market?
ANVISA follows stringent scientific evaluation and international standards before granting approval. Information on approved drugs and potential safety concerns is also available through ANVISA’s official communication channels.
6. Can drugs that are not approved in Brazil be imported?
Such situations may include specific regulatory pathways or exceptional cases such as importation for personal use under applicable regulatory requirements.
7. How can companies stay updated on new drug approvals in Brazil?
You can stay informed by following ANVISA’s official publications, newsletters, and digital platforms.
8. Does ANVISA approve traditional medicines?
The regulatory framework for phytotherapeutic medicines has undergone updates in recent years as part of ANVISA’s ongoing modernization of medicinal product regulations.
9. Does ANVISA collaborate with other regulatory agencies?
Yes. ANVISA actively collaborates with international regulatory authorities, promoting regulatory convergence and information exchange.
10. How does ANVISA ensure the quality of drugs manufactured in Brazil?
ANVISA conducts regular inspections of manufacturing facilities and enforces strict quality control measures to ensure compliance with Good Manufacturing Practices (GMP).
11. What happens if a drug approved in Brazil later shows safety concerns?
ANVISA continuously monitors medicines after approval and may issue warnings, restrict use, or recall products if safety risks are identified.
12. Is the approval process for OTC medicines different from prescription drugs?
In Brazil, OTC medicines are classified as Medicamentos Isentos de Prescrição (MIP) and must comply with the applicable regulatory framework defining the criteria and list of substances eligible for non-prescription status.
13. Are there plans to reform or modernize the drug approval process in Brazil?
ANVISA continuously works to modernize and improve its regulatory processes, aligning with international best practices while maintaining high safety standards.
Do you have questions about bringing your drug to the Brazilian market or navigating ANVISA approval requirements?
Our regulatory experts can support you throughout the drug approval process in Brazil and help you move forward with confidence.
